Checkpoint Inhibitor Combined With Tyrosine Kinase Inhibitor-the End or Beginning?

De-Rui Huang, DerekDerekDe-Rui HuangCHIH-HSIN YANG2023-03-022023-03-022020-031556-0864https://scholars.lib.ntu.edu.tw/handle/123456789/628827enCELL LUNG-CANCER; IMMUNE ESCAPE; ACTIVATION; ERLOTINIB; BLOCKADE; THERAPY; PD-L1; NSCLC[SDGs]SDG2[SDGs]SDG3Checkpoint Inhibitor Combined With Tyrosine Kinase Inhibitor-the End or Beginning?editorial10.1016/j.jtho.2019.12.121320938492-s2.0-85079693356WOS:000516801100010https://api.elsevier.com/content/abstract/scopus_id/85079693356